A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB15 (Proposed Aflibercept Biosimilar) and Eylea® in Subjects With Neovascular Age-related Macular Degeneration

This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, Pharmacokinetics (PK), and immunogenicity of SB15 compared to Eylea® in subjects with neovascular AMD.

开始日期2020-06-23

申办/合作机构

Samsung Bioepis Co., Ltd.

100 项与阿柏西普生物类似药 (Samsung Bioepis) 相关的临床结果

登录后查看更多信息

100 项与阿柏西普生物类似药 (Samsung Bioepis) 相关的转化医学

登录后查看更多信息

100 项与阿柏西普生物类似药 (Samsung Bioepis) 相关的专利（医药）

登录后查看更多信息

项与阿柏西普生物类似药 (Samsung Bioepis) 相关的文献（医药）

2025-01-09·Journal of Physical Chemistry Letters

Evaluating the Synergistic Effects of Multi-Epitope Nanobodies on BA.2.86 Variant Immune Escape

Article

作者: Liu, Jinxin ; Zhang, Enhao ; Duan, Lili ; Xu, Xiaole ; Zhang, John Z. H. ; Luo, Song ; Liang, Houde

Addressing the frequent emergence of SARS-CoV-2 mutant strains requires therapeutic approaches with innovative neutralization mechanisms. The targeting of multivalent nanobodies can enhance potency and reduce the risk of viral escape, positioning them as promising drug candidates. Here, the synergistic mechanisms of the two types of nanobodies are investigated deeply. Our research revealed that the Fu2-1-Fu2-2 system exhibited significant synergy, whereas the Sb#15-Sb#68 system demonstrated antagonism, in which entropy was the dominant contributor to antagonism. Conformational analysis further demonstrated that the presence of a monomeric nanobody influenced the flexibility of residues near other epitopes, thereby affecting the overall synergy of the systems. Moreover, we identified that changes in the hydrogen bond network and the charge of residues played a critical role in the binding between nanobodies and spike. We hope this study will provide novel insights into the development of multivalent nanobody combinations.

2024-08-01·Ophthalmology and Therapy

Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea®)

Article

作者: Lee, Jaeil ; Kim, Beom Chan ; Song, Jinsu ; Lee, Hangyeore ; Lee, Soye ; Huh, Jongcheol ; Kim, Dayoung ; Lee, Jungmin

INTRODUCTION:

SB15 is a proposed biosimilar product of reference aflibercept (Eylea^®), an approved biological drug product for retinal diseases including neovascular age-related macular degeneration (nAMD). This study aimed to assess the analytical similarity between SB15 and its commercially available reference product (RP) sourced from the United States (US-aflibercept) and European Union (EU-aflibercept) in terms of structural, physicochemical, and biological properties.

METHODS:

A panel of state-of-the-art analytical methods was used for the comprehensive characterization of SB15 and US/EU-aflibercept. In terms of the structural and physicochemical properties, primary structure; post-translational modifications (PTM); higher-order structure; purity and impurities; charge variants; and glycosylation were compared. In addition, biological characterization including mechanism of action (MoA)-related and Fc-related biological activities was conducted.

RESULTS:

Analytical similarity between SB15 and US/EU-aflibercept was demonstrated. The primary and higher-order structure of SB15 was confirmed to be comparable to that of US/EU-aflibercept. In addition, there were no meaningful differences in the physicochemical properties in terms of size and charge heterogeneity between SB15 and its RP. SB15 and RP were similar in biological activities including MoA-related binding activities, potencies, and Fc-related biological functions. Consequently, SB15 was confirmed to be highly similar to US/EU-aflibercept.

CONCLUSIONS:

Based on a comprehensive analytical similarity assessment of structural, physicochemical, and biological properties, SB15 was demonstrated to be highly similar to US/EU-aflibercept RP, supporting safe and effective use of SB15.

2023-12-01·BMJ open ophthalmology

Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial

Article

作者: Studnička, Jan ; Oh, Inkyung ; Csutak, Adrienne ; Yun, Cheolmin ; Ernest, Jan ; Vajas, Attila ; Sadda, SriniVas R ; Jang, Hyerin ; Choi, Wooree ; Enyedi, Lajos ; Tóth-Molnár, Edit ; Patel, Sunil ; Wylegala, Edward ; Veith, Miroslav ; Astakhov, Sergei ; Woo, Se Joon ; Sagong, Min ; Orski, Michal ; Bradvica, Mario

Background/aims:

To evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of SB15 versus reference aflibercept (AFL), and switching from AFL to SB15 in neovascular age-related macular degeneration (nAMD).

Design:

Prospective, double-masked, randomised, phase 3 trial.

Methods:

Participants with nAMD were randomised 1:1 to receive SB15 (N=224 participants) or AFL (N=225). At week 32, participants either continued on SB15 (SB15/SB15, N=219) or AFL (AFL/AFL, N=108), or switched from AFL to SB15 (AFL/SB15, N=111). This manuscript reports 1-year and switching results of secondary efficacy endpoints such as changes from baseline to week 56 in best-corrected visual acuity (BCVA), central subfield thickness (CST, from internal limiting membrane (ILM) to retinal pigment epithelium), and total retinal thickness (TRT, from ILM to Bruch’s membrane). Additional endpoints included safety, PK and immunogenicity.

Results:

Efficacy results were comparable between groups. The least squares mean (LSmean) change in BCVA from baseline to week 56 was 7.4 letters for SB15/SB15 and 7.0 letters for AFL/AFL (difference (95% CI)=0.4 (−2.5 to 3.2)). The LSmean changes from baseline to week 56 in CST and TRT were −119.2 µm and −132.4 µm for SB15/SB15 and −126.6 µm and −136.3 µm for AFL/AFL, respectively (CST: difference (95% CI)=7.4 µm (−6.11 to 20.96); TRT: difference (95% CI)=3.9 µm (−18.35 to 26.10)). Switched and non-switched participants showed similar LSmean changes in BCVA from baseline to week 56 (AFL/SB15, 7.9 letters vs AFL/AFL, 7.8 letters; difference (95% CI)=0.0 (−2.8 to 2.8)). Safety, PK and immunogenicity were comparable between groups.

Conclusions:

Efficacy, safety, PK and immunogenicity were comparable between SB15 and AFL and between switched and non-switched participants.

项与阿柏西普生物类似药 (Samsung Bioepis) 相关的新闻（医药）

2025-11-03

·药时代

一个月内，这款重磅眼科药物权益两次更替！涉及奥赛康、I-Mab以及云顶新耀

出海机会来了！欧美药企紧急寻找NLRP3创新药产品，IND-enabling阶段优先考虑，暂不考虑细胞疗法、基因疗法。希望产品具有明显的差异化优势！请感兴趣的公司立即联系药时代BD团队 BD@drugtimes.cn 正文共：1900字预计阅读时间：5分钟 “女王已死，新王当立”，这句最早可追溯至15世纪的法国谚语，用在当下眼科药物市场，也挺合适。从雷珠单抗，到阿柏西普，再到如今的法瑞西单抗（Vabysmo），围绕眼科明星靶点VEGF的战争蔓延至今。头对头Vabysmo 2025年10月29日，NovaBridge（新桥生物）宣布旗下子公司Visara，将其眼科药物VIS-101权益许可给云顶新耀。据外媒citeline报道，前者有望于2026年第一季度启动VIS-101与Vabysmo的Ⅲ期头对头比较研究。 VIS-101与Vabysmo同靶点，能同时阻断血管生成素-2（Ang-2）与血管内皮生长因子-A（VEGF-A）两条致病关键通路，这两种通路都能破坏血管的稳定性，使血管发生渗漏，增加炎症的发生。 VIS-101已于美国及中国完成初步安全性与剂量递增研究，目前正于中国进行随机分组的剂量范围II期临床试验，预计将于2026年具备进入III期临床试验的条件，2028年有望数据读出。 Vabysmo，如今罗氏眼科业务的台柱子。上市3年（2024）年销售额就达到了44亿美元（+68%）。根据云顶新耀新闻稿披露，2024年全球抗VEGF眼科药物市场规模已达约230亿美元，预计到2030年将超过400亿美元。面对如此大的“蛋糕”，盯上VIS-101新王之位的人并不少。信达刚刚与Ollin达成出海交易的IBI324，也是相同靶点，且也宣布了在美开展与Vabysmo的头对头研究，不过目前尚处Ib期阶段，预计2026年第一季度数据读出。相比之下，目前VIS-101的进展还是快上一些。复杂的权益更替暂不谈VIS-101的早期临床表现，就该药物的权益更替也很有故事。 VIS-101并非新桥生物原研。今年10月17日，北京奥赛康药业子公司AskGene将ASKG712（曾用名VIS-101），在大中华地区、新加坡、泰国、马来西亚、印度尼西亚、越南、韩国及印度的权益许可给了NovaBridge子公司Visara。根据协议，Visara将向AskGene支付700万美元的一次性、不可退还、不可抵扣的首付款（在协议生效后的30个工作日内），AskGene有权收取最高8900万美元的里程碑付款，及一定比例的特许权使用费。不到一个月时间，10月29日，Visara又将VIS-101在大中华区、新加坡、韩国及若干东南亚国家的权益许可给了云顶新耀，首付款700万美元，里程碑付款最高8900万美元。也就是说，在两笔BD交易中，Visara起到了类似桥梁的作用（Visara也确实是为了VIS-101新成立的）。从某种意义而言，AskGene的首付款就是云顶新耀出的。新桥生物为何如此，暂不可知。仅从新桥生物股价(NASDAQ:NBP)来看，截止10月31日收盘，该公司股价大涨8.79%，报4.95美元/股，总市值为5.71亿美元。新桥生物动作频频相较于新桥生物这个名字，I-Mab这个曾用名更为人所熟知。 I-Mab前身是天境生物，2020年成功登陆纳斯达克，2024年2月完成境内外拆分，境外主体保留I-Mab名称，专注海外市场发展，中国资产归于TJ Bio。 2025年8月，云顶新耀宣布增加对I-Mab的战略投资（3090万美元），成为其第一大股东，目前持股比例16.0%，其次是康桥资本持股10.4%。 2025年10月16日，I-Mab发布新闻稿计划港交所上市，公司更名为新桥生物，同时宣布任雷鸣（Kyler Lei）为公司首席财务官。 2025年10月29日，新桥生物宣布正式启用新公司名称及新股票代码“NBP”（Nasdaq: NBP）。 2025年10月30日，新桥生物还对外宣布任命云顶新耀总裁、首席财务官兼执行董事何颖先生（Ian Woo）为公司董事会成员，而上述两笔BD交易的披露时间，正好在这一系列的战略变革之中。蓝海不蓝虽然资本运作比较复杂，但眼科抗VEGF药物市场的竞争却较为明朗。单靶点药物存在疗效递减等局限性，加之患者间的个体差异导致治疗反应和副作用的显著变异。 VEGF双靶点药物Vabysmo以“疗效稳定+耐受性良好+更优剂型”的优势，强势杀出，引领眼科药物新一轮变革。目前，VEGF双靶点药物中，全球进展第二的就是VIS-101，其主要权益在云顶新耀和蔼睦医疗（AffaMed）手中。2022年，奥赛康将该药在全球亚洲以外地区和日本市场权益授权给了和蔼睦医疗。其次，临床进展较快的还有康哲药业/友芝友生物、星眸生物、嘉因生物、BI、信达生物/Ollin等。只能说，蓝海不蓝，谁能继罗氏之后第二个撞线，药时代将持续关注。图片来源：即梦AI 震惊！FDA药品审批主管被停职，快速审批程序引争议 2025-11-03 最高年薪50+万！复旦大学招聘“合成生物学 + 药学”博士后 2025-11-02 精选优质、协作共赢！2025中国生物医药领跑者100榜单发布 2025-11-01 版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩内容！

引进/卖出临床申请临床1期临床2期基因疗法

2025-10-29

·Business Wire

Samsung Bioepis to Commercialize BYOOVIZ ® (ranibizumab) in Europe from January 2026

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe. We will work closely with Biogen to ensure a seamless transition and the continued delivery of services to our customers and patients in Europe. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe. We will work closely with Biogen to ensure a seamless transition and the continued delivery of services to our customers and patients in Europe,” said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial, at Samsung Bioepis. “Samsung Bioepis will continue to broaden our reach to patients across Europe by reinforcing our leadership and expertise in biosimilars.” BYOOVIZ (ranibizumab) was approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). BYOOVIZ became commercially available in several countries within Europe from March 2023. OPUVIZ (aflibercept) was approved by the EC in November 2024 and by the Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025 for the treatment of patients with Wet AMD, Visual Impairment due to Macular Oedema Secondary to RVO, Visual Impairment due to Diabetic Macular Edema (DME), and Visual Impairment due to mCNV. OPUVIZ will not be launched until after the lapse or revocation of relevant patent(s) for the reference biologic Eylea that also covers OPUVIZ in Europe. About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – LinkedIn, X. Lucentis is a trademark of Genentech, Inc. Eylea is a trademark of Bayer AG

上市批准引进/卖出

2025-10-27

·百度百家

高速发展的国内眼科新药市场：创新与资本的双驱动

【眼科领域的崛起】近年来，国内生物医药研发领域蓬勃发展，而眼科作为感知世界的重要器官，其复杂性是不言而喻的。从角膜到视网膜，每一个组成部分都可能影响我们的视力和视觉。尽管眼科疾病病因的科学研究进展相对缓慢，眼科药物研发也面临着靶点和作用机制上突破的挑战，但眼科在生物医药研发中的地位逐渐提升。新技术和新剂型的发展为眼科药物研发带来了新的希望，给药途径的创新也成为了研发的重点。尽管当前国内眼科药物的开发主要集中在仿制药领域，以抗感染、消炎和缓解视疲劳为主要治疗方向，但在创新药的研发方面，尤其是致盲性眼病的研发，我国与国际水平仍存在显著差距。然而，令人欣喜的是，近年来我国眼科药物市场格局正在发生深刻变化。新旧势力之间的竞争日趋激烈，而一些企业已经早早占据了市场的领先地位。展望未来，我国眼科药物市场有望在2020年迎来新的发展纪元。【欧康维视的成功】其中，欧康维视无疑是2020年眼科行业内最为耀眼的企业之一。成立于2018年2月的欧康维视，在短短两年内便成功在港股上市，成为了行业内的佼佼者。成立仅两年，欧康维视在资本支持下迅速成长并在港股上市。其上市过程吸引了摩根士丹利和高盛等知名机构的参与，斯道资本、淡马锡、奥博资本、博裕资本等14家知名机构更是成为了其基石投资者。欧康维视的成功上市，无疑为我国眼科药物的创新发展注入了新的活力。【新势力的崛起】从创立到成功上市，欧康维视仅用了短短两年时间。这两年间，公司经历了从2019年两轮融资2亿美元到2020年港交所上市募资14亿港币的飞跃。从保荐人到基石投资者，欧康维视的成长过程中，资本运作的痕迹清晰可见，这也使其成为了资本圈的一个标杆项目。新兴企业如极目生物等通过资本支持与国际技术合作，逐步在眼科药物市场上崭露头角。2019年5月，极目生物在南丰生命科技和鼎丰生科资本的共同孵化投资下应运而生。2020年7月，该公司成功筹集了3200万美元的A轮融资，为后续发展注入了强劲动力。【资本和团队的布局】欧康维视背后的资本方，如创始投资人通和毓承，早已洞察到肿瘤免疫领域赛道过于拥挤，需要寻找新的投资方向。眼科领域，作为被选中的黄金赛道，吸引了他们的目光。随后，公司迅速组建了包括眼科制药领域资深人士在内的团队，并建立了丰富的产品组合。这样的团队架构使得业务熟悉、配合默契、磨合期短，确保了公司的高效运转。极目生物的管理团队实力不俗，其核心成员均来自爱尔康、艾尔建等眼科行业的佼佼者，并曾在中国成功推动眼科产品的上市。然而，目前公司的产品组合尚待丰富。【眼科创新药的未来】从产品组合的角度来看，欧康维视的策略也相当出色。他们不仅成功地自主研发了三个商业化阶段的产品，还从外部引进了阿柏西普生物类似药，进一步丰富了产品线。这样的梯度布局既保证了公司能够快速实现现金流，也为后续的新药研发奠定了坚实基础。特别值得一提的是，OT-401（YUTIQ）项目，目前正处于临床试验3期阶段，并计划于2022年提交上市申请。这款玻璃体内植入剂专为治疗慢性非感染性葡萄膜炎设计，具有广阔的市场前景。此外，该项目的真实世界研究正在海南省博鳬超级医院展开，这将为3期临床试验数据提供有力的支持。随着全球一体化进程的加速，跨国药企也纷纷进入中国市场，带来了创新产品和先进技术。这些药品不仅提升了我国病患的治疗水平，也为本土企业提供了仿制对象和研发灵感。随着技术进步，眼科市场有望满足更多未被满足的临床需求，推动创新药物研发。【欧康维视】欧康维视无疑是2020年眼科行业内最为耀眼的企业之一，其在资本支持下的迅速成长和多元化的产品组合，展示了眼科药物的市场潜力。【极目生物】极目生物于2020年从美国Clearside公司引进了曲安奈德脉络膜上腔注射混悬液，这款产品主要用于治疗葡萄膜炎性黄斑水肿，并在同年底获得中国临床试验的批准，为公司的产品线增添了重要的一笔。【 AffaMed 】美国Clearside公司以其独特的脉络膜上腔注射技术为基石，已成功开发出多种眼科创新药物。2020年10月14日，生物医药公司AffaMed Therapeutics与EverInsight Therapeutics达成最终合并协议，合并后的公司仍沿用AffaMed Therapeutics的名称，并将专注于眼科及中枢神经系统药物的开发和推广。【典晶生物】典晶生物在2020年完成了5000万美元的A轮融资，总部和研发中心位于苏州工业园区，致力于组建强大的团队，并在小分子眼科药物的研发和国际临床及注册事务上取得了一系列重要进展。公司的核心成员拥有丰富的国际经验和强大的科研能力。总之，对于资本而言，眼科领域仅是其在投资立项时发现的新机遇。然而，眼科临床仍存在大量未被满足的需求。与发达市场相比，中国目前的眼科技术和疗法显得相对滞后。愿在资本的推动下，各方能共同加大投入，致力于研发出突破性的眼科新药和疗法。特别是在基因治疗和革新性给药技术等高科技领域，我们应深入探索，以期最终能为广大眼疾患者带来福音。

引进/卖出

100 项与阿柏西普生物类似药 (Samsung Bioepis) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XX44 S01LA05	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病性视网膜病变	美国	Samsung Bioepis Co., Ltd.	2024-05-20
糖尿病性黄斑水肿	韩国	Samsung Bioepis Co., Ltd.	2024-02-23
近视脉络膜新生血管	韩国	Samsung Bioepis Co., Ltd.	2024-02-23
视网膜静脉阻塞相关黄斑水肿	韩国	Samsung Bioepis Co., Ltd.	2024-02-23
湿性年龄相关性黄斑变性	韩国	Samsung Bioepis Co., Ltd.	2024-02-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04450329 (CTgov)	临床3期	湿性年龄相关性黄斑变性	449	SB15 (Proposed aflibercept biosimilar) (SB15 (Proposed Aflibercept Biosimilar))	衊範夢蓋鏇顧糧積顧鏇(鹽獵製夢鹽製夢壓繭積) = 醖壓築膚憲簾艱獵鹹壓襯淵廠範構願觸廠壓憲 (製鏇積簾選鹹齋鬱糧願, 0.56) 更多	-	2024-02-05
				SB15 (Proposed aflibercept biosimilar)+Eylea (Eylea (Aflibercept))	衊範夢蓋鏇顧糧積顧鏇(鹽獵製夢鹽製夢壓繭積) = 窪餘鹽簾衊顧膚蓋構廠襯淵廠範構願觸廠壓憲 (製鏇積簾選鹹齋鬱糧願, 0.57) 更多
EURETINA2023 人工标引	临床3期	湿性年龄相关性黄斑变性	438	SB15	繭繭衊網遞鏇簾顧築鑰(鏇淵窪築衊遞廠夢壓襯) = 顧築觸鏇齋膚糧膚壓艱夢壓網鹹積築鏇窪餘壓 (齋膚鬱夢顧醖構網積鏇 ) 更多	积极	2023-10-05
				Aflibercept	繭繭衊網遞鏇簾顧築鑰(鏇淵窪築衊遞廠夢壓襯) = 簾蓋遞壓鹹積構衊醖鬱夢壓網鹹積築鏇窪餘壓 (齋膚鬱夢顧醖構網積鏇 ) 更多
EURETINA2023 人工标引	临床3期	年龄相关性黄斑变性	449	SB15	築壓網衊選鏇鑰繭衊壓(糧衊齋鬱憲鏇觸淵壓願) = 簾獵窪襯選鏇齋鏇鏇簾網願顧襯鹹鹽餘蓋獵鬱 (獵鹹壓鏇衊襯獵願鑰鑰 )	相似	2023-10-05
				Aflibercept	築壓網衊選鏇鑰繭衊壓(糧衊齋鬱憲鏇觸淵壓願) = 憲鬱鏇憲顧鏇憲餘遞鹽網願顧襯鹹鹽餘蓋獵鬱 (獵鹹壓鏇衊襯獵願鑰鑰 )
EURETINA2023	N/A	湿性年龄相关性黄斑变性	-	SB15	顧鬱簾構遞積簾鏇鹹願(築繭膚獵衊範衊繭積願) = 構願願窪製願鏇齋鹽淵壓壓構憲鬱齋願繭鹽齋 (窪鑰齋構製構鹹淵鏇鹽 ) 更多	-	2023-10-05
				AFL	顧鬱簾構遞積簾鏇鹹願(築繭膚獵衊範衊繭積願) = 淵選構醖壓糧築選顧範壓壓構憲鬱齋願繭鹽齋 (窪鑰齋構製構鹹淵鏇鹽 ) 更多
NCT04450329 (Pubmed)	临床3期	湿性年龄相关性黄斑变性	449	SB15	夢膚壓窪憲選淵餘顧膚(鹹選構窪淵鏇壓選鑰鹹) = 膚鑰憲壓襯襯網膚淵糧壓構鹽廠餘鑰鬱糧構網 (遞鹹積廠餘窪衊蓋窪願 ) 更多	-	2023-06-08
				AFL	夢膚壓窪憲選淵餘顧膚(鹹選構窪淵鏇壓選鑰鹹) = 鬱鹽顧鏇淵積遞蓋簾夢壓構鹽廠餘鑰鬱糧構網 (遞鹹積廠餘窪衊蓋窪願 ) 更多
NCT04450329 (ARVO2023)	临床3期	湿性年龄相关性黄斑变性	449	SB15 2 mg	襯簾築願範製鬱網艱鑰(襯網願糧壓衊衊糧鹹簾) = 網襯獵積壓鬱製選鏇鹽構簾糧艱鏇顧築壓構齋 (艱窪選膚鹽廠廠顧衊觸 )	积极	2023-06-01
				Aflibercept	襯簾築願範製鬱網艱鑰(襯網願糧壓衊衊糧鹹簾) = 顧憲淵艱選衊積淵鏇夢構簾糧艱鏇顧築壓構齋 (艱窪選膚鹽廠廠顧衊觸 )
AAO2022	临床3期	-	-	SB15	鑰鑰製製遞夢蓋壓鹽壓(積齋製醖襯憲網網醖鏇) = 構製襯範鑰觸壓蓋廠鹹憲築鑰襯願積鏇艱簾襯 (觸製獵衊蓋夢觸壓窪憲 )	积极	2022-09-29
				Aflibercept	鑰鑰製製遞夢蓋壓鹽壓(積齋製醖襯憲網網醖鏇) = 積憲鏇鏇淵築鏇獵餘範憲築鑰襯願積鏇艱簾襯 (觸製獵衊蓋夢觸壓窪憲 )